Tekmira’s Partner Presents New Clinical Data for LNP-Enabled Patisiran (ALN-TTR02)

[GlobeNewswire] – VANCOUVER, British Columbia — Tekmira Pharmaceuticals Corporation , a leading developer of RNA interference (RNAi) therapeutics, today reported that Alnylam Pharmaceuticals, Inc. presented new clinical … more

View todays social media effects on TKMR

View the latest stocks trending across Twitter. Click to view dashboard

See who Tekmira is hiring next, click here to view